Chang Xu, MD
Nephrology · Bronx, NYNPI 1619112075
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Biogen at 36.5% of the total. 2025 is the largest year on record at $4,901, 4.7 times the $1,036 reported in 2019.
Across 134 payments — averaging $81.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$4K
- Travere Therapeutics, Inc.$3K
- AstraZeneca$2K
- Otsuka America Pharmaceutical, Inc.$207
- Mallinckrodt Enterprises LLC$194
- Vertex$178
- plus $1K from 12 others
Across 13 payments — averaging $18,920 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$209K
- AstraZeneca$19K
- CSL Behring$18K
- Novartis$143
What the payments were for
- Consulting fees$2,70025%
- Travel & lodging$3,87435%
- Food & beverage$4,27339%
- Education$681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 31 | $3,988 |
| Travere Therapeutics, Inc. | 6 | $2,940 |
| AstraZeneca(2 entities) | 34 | $2,387 |
| Otsuka America Pharmaceutical, Inc. | 6 | $207 |
| Mallinckrodt Enterprises LLC | 12 | $194 |
| Vertex | 3 | $178 |
| GSK | 2 | $150 |
| Amgen(2 entities) | 8 | $147 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Vifor Pharma, Inc. | 7 | $122 |
| OPKO Pharmaceuticals, LLC | 6 | $115 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $108 |
| Mallinckrodt Hospital Products Inc. | 4 | $86 |
| Sanofi | 4 | $68 |
| Akebia Therapeutics Inc | 2 | $41 |
| Shire North American Group Inc | 2 | $30 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Dentsply Sirona Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$125
- INJECTAFER$124
How this compares
$10,915 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $7,439 |
| Metolazone | 14 | $337 |
| Metoprolol Succinate | 14 | $136 |
| Quetiapine Fumarate | 28 | $118 |
| Amiodarone Hcl | 14 | $50 |
| Donepezil Hcl | 14 | $38 |
| Torsemide | 14 | $37 |
| Pantoprazole Sodium | 14 | $31 |
| Atorvastatin Calcium | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bronx
- Bruce SpinowitzBronx$465K
- Joel NeugartenBronx$248K
- Enver AkalinBronx$101K
- John KangBronx$93K
- Daniel AddankiBronx$54K
- Chaim CharytanBronx$34K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.